LifeStance Health Group, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
OmniAb (OABI) +13% to $5.43, raising 2026 cash flow guidance to $49M-$53M. Freenome (FRNM) +4% to $16.03 after FDA approvals. Exelixis (EXEL) +$59.11, Q2 profit $212M. LifeStance (LFST) +$13.15, Q2 revenue +26% to $435.4M. Faeth (FTH) +$40.89, Q2 loss $16M.
Lifestance Health Group (LFST) stock hit a 52-week high at $12.97, now trading at $13 with a $4.81B market cap. The stock surged 129.51% over the past year, driven by strong Q2 2026 earnings and raised full-year outlook. Revenue grew 26% to $435.35M, with adjusted EBITDA up 94% to $66M, according to the company.
LifeStance Health Group (LFST) reported Q2 2026 revenue of $435.35M and net income of $23.61M, reversing a year-ago net loss. The company completed a $97.19M share repurchase and authorized a new buyback up to $100M. Full-year 2026 revenue guidance was raised to $1.69B-$1.73B.
Over the past 7 days, alphai's AI scored 2 news stories mentioning LFST (LifeStance Health Group, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent LFST coverage spans earnings, financial news and insider activity.
In the last 30 days, LFST insiders filed 6 SEC Form 4 transactions — no purchases and 6 sales ($152.0M). The most active reporter was DeLuca Teresa with 2 filings. 33% of those filings were made under pre-arranged Rule 10b5-1 plans.
Revenue beat and raised guidance suggest stronger demand for mental‑health services.
Strong earnings beat and outlook raise upside potential.
Profitability turn plus higher revenue outlook and an additional buyback tranche are likely to support near-term sentiment and per-share expectations.
Strong earnings and guidance beats support momentum and reduce near-term downside risk for LFST relative to the peer set.
The insider sale is a modest, non-fundamental signal, but it coincides with the stock near its 52-week high and alongside reported buybacks.
alphai scores every news story that mentions LFST with an AI model for sentiment and relevance, and aggregates insider trades from LifeStance Health Group, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
OmniAb (OABI) +13% to $5.43, raising 2026 cash flow guidance to $49M-$53M. Freenome (FRNM) +4% to $16.03 after FDA approvals. Exelixis (EXEL) +$59.11, Q2 profit $212M. LifeStance (LFST) +$13.15, Q2 revenue +26% to $435.4M. Faeth (FTH) +$40.89, Q2 loss $16M.
2 min readLifestance Health Group (LFST) stock hit a 52-week high at $12.97, now trading at $13 with a $4.81B market cap. The stock surged 129.51% over the past year, driven by strong Q2 2026 earnings and raised full-year outlook. Revenue grew 26% to $435.35M, with adjusted EBITDA up 94% to $66M, according to the company.
2 min readLifeStance Health Group (LFST) reported Q2 2026 revenue of $435.35M and net income of $23.61M, reversing a year-ago net loss. The company completed a $97.19M share repurchase and authorized a new buyback up to $100M. Full-year 2026 revenue guidance was raised to $1.69B-$1.73B.
4 min readThe article highlights Q2 results for outpatient and specialty care firms. Surgery Partners (SGRY) reported slowest revenue growth and weaker full-year guidance, with the stock down 1.4% to $15.32. LifeStance (LFST) revenue rose to $435.4M (+26.1%) and shares rose 18.3% to $12.27. U.S. Physical Therapy (USPH) revenue $214.1M (+8.5%) and shares $81.96. Encompass Health (EHC) revenue $1.60B (+9.6%) and shares $124.69. agilon health (AGL) revenue $1.49B (+7.2%), shares $87.56.
6 min readLifeStance Health director Teresa DeLuca sold 20,441 shares of LFST on Aug. 13, 2026 for about $249,993 at $12.23 per share, according to an SEC filing. The stock was near its 52-week high. The company also reported Q2 2026 results above estimates and raised its full-year outlook.
3 min readDeLuca Teresa sold 20,441 shares of LifeStance Health Group, Inc. (LFST) at $12.23 ($0.25M total) on 2026-08-13.
1 min readLifeStance Health Group, Inc. said a shareholder group led by TPG GP A, LLC, with James G. Coulter and Jon Winkelried, disclosed beneficial ownership of 98,101,407 common shares via TPG VIII Lynnwood Holdings Aggregation, L.P. The stake equals 25.7% of 382,055,609 shares outstanding as of July 29, 2026, per a Schedule 13G filing.
3 min readYawaog Enterprises Corp (LFST) disclosed via a Rule 144 filing that an insider plans to sell 7,500 vested common shares through Fidelity Brokerage Services LLC on NASDAQ. The filing cites an indicated aggregate market value of $95,118.49 as of the proposed transaction. It also references prior sales of 20,441 shares on Aug. 13, 2026 for $249,993.43.
2 min readBurdick Kenneth A sold 500,000 shares of LifeStance Health Group, Inc. (LFST) at $11.51 ($5.76M total) on 2026-08-11.
2 min readLifeStance Health Group (LFST) reported Q2 revenue of $435.4M, above estimates of $414.6M, and adjusted EPS of $0.11 vs $0.08. Adjusted EBITDA was $66.04M. The company raised full-year revenue guidance to $1.71B and EBITDA guidance to $225M midpoint, citing clinician productivity, specialty services growth, and digital workflow tools.
6 min read
